Lucid Diagnostics Valuation
| LUCD Stock | USD 1.12 0.02 1.75% |
Today, the firm appears to be undervalued. Lucid Diagnostics secures a last-minute Real Value of $1.76 per share. The latest price of the firm is $1.12. Our model forecasts the value of Lucid Diagnostics from analyzing the firm fundamentals such as Operating Margin of (15.08) %, shares outstanding of 108.19 M, and Return On Equity of -18.97 as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Lucid Diagnostics' price fluctuation is dangerous at this time. Calculation of the real value of Lucid Diagnostics is based on 3 months time horizon. Increasing Lucid Diagnostics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Lucid stock is determined by what a typical buyer is willing to pay for full or partial control of Lucid Diagnostics. Since Lucid Diagnostics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lucid Stock. However, Lucid Diagnostics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.12 | Real 1.76 | Hype 1.12 | Naive 1.18 |
The real value of Lucid Stock, also known as its intrinsic value, is the underlying worth of Lucid Diagnostics Company, which is reflected in its stock price. It is based on Lucid Diagnostics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Lucid Diagnostics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Lucid Diagnostics helps investors to forecast how Lucid stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lucid Diagnostics more accurately as focusing exclusively on Lucid Diagnostics' fundamentals will not take into account other important factors: Lucid Diagnostics Total Value Analysis
Lucid Diagnostics is now forecasted to have valuation of 191.04 M with market capitalization of 121.18 M, debt of 21.25 M, and cash on hands of 34.46 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lucid Diagnostics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
191.04 M | 121.18 M | 21.25 M | 34.46 M |
Lucid Diagnostics Investor Information
About 35.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.17. Lucid Diagnostics had not issued any dividends in recent years. Based on the key indicators related to Lucid Diagnostics' liquidity, profitability, solvency, and operating efficiency, Lucid Diagnostics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.Lucid Diagnostics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lucid Diagnostics has an asset utilization ratio of 14.15 percent. This indicates that the Company is making $0.14 for each dollar of assets. An increasing asset utilization means that Lucid Diagnostics is more efficient with each dollar of assets it utilizes for everyday operations.Lucid Diagnostics Ownership Allocation
Lucid Diagnostics maintains a total of 108.19 Million outstanding shares. Lucid Diagnostics holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lucid Diagnostics Profitability Analysis
The company reported the previous year's revenue of 4.35 M. Net Loss for the year was (45.53 M) with loss before overhead, payroll, taxes, and interest of (2.82 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Lucid Diagnostics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Lucid Diagnostics and how it compares across the competition.
About Lucid Diagnostics Valuation
The stock valuation mechanism determines Lucid Diagnostics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Lucid Diagnostics. We calculate exposure to Lucid Diagnostics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lucid Diagnostics's related companies.Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange.
Lucid Diagnostics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Lucid Diagnostics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 50.5 M |
Complementary Tools for Lucid Stock analysis
When running Lucid Diagnostics' price analysis, check to measure Lucid Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucid Diagnostics is operating at the current time. Most of Lucid Diagnostics' value examination focuses on studying past and present price action to predict the probability of Lucid Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lucid Diagnostics' price. Additionally, you may evaluate how the addition of Lucid Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |